57 results about "Viral glycoprotein" patented technology

In aspects, the present disclosure provides a recombinant fusion protein comprising, consisting essentially of, or consisting of (a) a rhabdoviral G glycoprotein or a functional fragment or derivative thereof and (b) a targeting molecule, wherein the targeting molecule targets the recombinant fusion protein to a hematopoietic stem cell (HSC). Additional aspects are as described herein.

Provided herein are hantivirus antibodies. These hantivirus antibodies bind to the Gn and / or Gc subunits of a hantavirus glycoprotein and have broad neutralizing activity against an epitope of different hantavirus species. Such antibodies are used in methods of inducing an immune response and methods of inhibiting hantavirus infection. Additionally provided are methods of treating an infectious disease using such antibodies.

The invention relates to the field of viral vectors, in particular to a modified viral vector as well as a preparation method and application thereof. The invention discloses a modified viral vector, the surface of the modified viral vector contains viral glycoprotein, and the ability of the viral glycoprotein to bind to a ligand or receptor of the viral glycoprotein on the surface of a cell is weakened.

The present disclosure relates to viral glycoprotein variants with reduced (e.g., abolished) binding to low-density lipoprotein receptor (LDL-R) compared to a reference viral glycoprotein. Recombinant viruses pseudotyped with viral glycoprotein variants described herein and optionally an envelope surface-bound targeting molecule (e.g., an anti-CD3 scFv), methods of producing thereof, and methods of using thereof, are also provided.

The invention relates to the field of aquaculture, in particular to a preparation method and application of a recombinant live vector vaccine for infectious hematopoietic necrosis of fish. In order to solve the problem of prevention and control of the infectious hematopoietic necrosis of the fish in the aquatic product industry, a replication-defective adenovirus type 5 is selected as a target gene expression vector to construct a recombinant adenovirus vector comprising a glycoprotein gene and a nucleoprotein gene of the infectious hematopoietic necrosis virus of the fish, and a recombinant virus is obtained; the safe and effective recombinant live vector vaccine for the infectious hematopoietic necrosis of the fish is created. According to the vaccine, immunization is carried out on fishes in a soaking or bait feeding mode, the total CPM of the fishes immunized by the vaccine is 6.67%, and the total CPM of the fishes in a non-immunized control group is 94.00%. In addition, the RPS of the vaccination group fish and the RPS of the empty vector control group fish are 92.90% and 9.22% respectively. The method is at a leading level in the field of fish biological medicines at present and has remarkable creativity.

In aspects, the present disclosure provides an enveloped delivery vehicle (EDV), comprising, consisting of, consisting essentially of: (1) an envelope membrane; (2) at least one first recombinant viral membrane glycoprotein (VMG) incorporated into the envelope membrane comprising a fusion protein comprising (A) a fusogenic membrane glycoprotein (FMG) comprising a substantially intact FMG and (B) a first targeting molecule; and (3) at least one second recombinant VMG incorporated into the envelope membrane comprising a fusion protein comprising (A) a FMG comprising a substantially intact FMG and (B) a second targeting molecule; wherein the first targeting molecule and the second targeting molecule are not the same. In aspects, the present disclosure provides methods of generating EDVs described herein. In aspects, the present disclosure provides a method of improving the cell infection efficiency of an EDV as described herein. Additional aspects are as described herein.

The present invention relates to synthetic designs or chimeric proteins for pseudotyping baculovirus (Autographa californica nuclear polyhedrosis virus) with the rabies virus glycoprotein G (gG) on its surface (Bac::gG-FL), which can be used in anti-rabies vaccine formulations. The chimeric protein is designed from a gene cassette containing gene fragments of the ectodomain of the G glycoprotein of the Pasteur strain rabies virus, a linker of 7 amino acids (GGGGSGG), as well as transmembrane (TM) and cytoplasmic (CT) regions of the gp64 baculovirus protein, with the arrangement of the sequences in the designed gene cassette being shown in figure 1.

The present disclosure provides virus-like particles (VLPs) comprising: i) a CRISPR-Cas effector polypeptide; ii) a recombinant lentivirus comprising a nucleotide sequence encoding a therapeutic polypeptide having a length of from about 250 amino acids to about 3,000 amino acids, where the VLP comprises a pseudotyping viral glycoprotein and / or a polypeptide that provides for binding to a target cell. The present disclosure provides systems for producing a VLP. The present disclosure provides methods of delivering a therapeutic protein, using a VLP of the present disclosure.

An extracellular vesicle. The surface of the extracellular vesicle comprises at least part of a viral envelope glycoprotein or a variant thereof; the at least part of the viral envelope glycoprotein or the variant thereof does not bind to a receptor or the binding to a receptor is inhibited; and the extracellular vesicle is difficult to infect a cell by binding to a glycoprotein receptor. When the extracellular vesicle is used for delivering a target protein, the targeting performance of the extracellular vesicle is significantly improved. When an extracellular vesicle membrane expresses a hydrophobic protein, the expression and purification of the hydrophobic protein are facilitated.

The present invention relates to polynucleotides comprising a sequence of a live, infectious, attenuated Flavivirus wherein a nucleotide sequence encoding at least a part of a Filovirus glycoprotein is located at the intergenic region between the E and NS1 gene of said Flavivirus, such that a chimeric virus is expressed, characterised in that the encoded sequence C terminally of the E protein of said Flavivirus and N terminally of the signal peptide of the NS1 protein of said Flavivirus comprises in the following order: a further signal peptide of a Flavivirus NS1 protein, a filovirus glycoprotein wherein the N terminal signal peptide is absent, a TM domain of a flaviviral E protein.

Device for the preventive blocking of neurotropic viruses in the peripheral nervous system, comprising a biochemical injection system for the localized release of a neurospecific binding molecule, a detection unit for the identification of viral particles in neuromuscular tissue, and a receptor bait structure for binding viral glycoproteins with affinity for neuronal receptors, characterized in that the device prevents retrograde axonal viral transmission without permanently impairing the conductivity of the nerve tissue.

Provided herein are particles comprising a fusion molecule comprising an adhesion molecule linked to a co-stimulatory molecule or an activating molecule; the present invention relates to fusion molecules, as well as vectors such as lentiviral vectors comprising the fusion molecules, cells comprising the fusion molecules, and methods of using the fusion molecules. The particle may be a lentiviral particle that displays a fusion molecule on a surface of the particle, the fusion molecule comprising: a) a CD58 extracellular domain or a functional fragment thereof, b) an antigen-binding fragment of an anti-CD3 antibody, and c) a CD80 or CD86 extracellular domain or a functional fragment thereof; and a viral glycoprotein (G protein).

The compositions and methods are described for generating an immune response to a hemorrhagic fever virus such as ebolavirus, Marburgvirus, or arenavirus. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to a member of genus Ebolavirus (such as a member of species Zaire ebolavirus), a member of genus Marburgvirus (such as a member of species Marburg marburgvirus), or a member of genus Arenavirus (such as a member of species Lassa virus) in the subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and / or treat an infection caused by ebolavirus, Marburgvirus, or arenavirus.

The present invention provides a Nipah virus (NiV) vaccine composition comprising (i) a messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) encoding a soluble Nipah virus glycoprotein (soluble NiV-G) fused to a human type I collagen alpha 1 (COL1A1) signal peptide, (ii) an mRNA comprising an ORF encoding a full length NiV-G, and (iii) a vaccine composition comprising (i) a messenger ribonucleic acid (mRNA) encoding an ORF encoding a full length NiV-G signal peptide. (iii) an mRNA comprising an ORF encoding a full-length Nipah virus fusion protein (full-length NiV-F) or (iv) an mRNA comprising an ORF encoding a full-length NiV-G, and an mRNA comprising an ORF encoding a full-length NiV-F, and a method of inducing an immune response against Nipah virus by administering to a subject in need thereof an effective amount of a Nipah virus vaccine composition.

The present disclosure provides virus-like particles (VLPs) comprising: i) a CRISPR-Cas effector polypeptide; ii) a recombinant lentivirus comprising a nucleotide sequence encoding a therapeutic polypeptide having a length of from about 250 amino acids to about 3,000 amino acids, where the VLP comprises a pseudotyping viral glycoprotein and / or a polypeptide that provides for binding to a target cell. The present disclosure provides systems for producing a VLP. The present disclosure provides methods of delivering a therapeutic protein, using a VLP of the present disclosure.

The invention relates to a preparation method and application of a probe based on wheat germ lectin. The probe is provided with a core-shell structure, and the core-shell structure is provided with a core and a shell wrapping the outer surface of the core. The core of the core-shell structure is Fe3O4 nanoparticles; the shell comprises a first cationic polymer layer, a gold nanoparticle layer, a second cationic polymer layer, a first quantum dot layer, a third cationic polymer layer, a second quantum dot layer and a wheat germ agglutinin layer which are sequentially coated from the outer surface of the core to the outside. The probe has relatively strong magnetic response capability, colorimetric signals, fluorescence signals and capability of capturing various virus glycoproteins; the MAuDQD-coated WGA-LFA method based on the probe provided by the invention is relatively wide in target detection object range, relatively high in detection sensitivity, relatively high in accuracy and relatively short in detection time.

The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that may introduce an epitope that is recognized by an antibody from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.

Provided herein are particles containing a fusion molecule comprising an adhesion molecule linked to a costimulatory molecule or an activation molecule, as well as vectors such as lentiviral vectors containing the same, cells containing the same, and methods for using the same. The particle may be a lentiviral particle that displays a fusion molecule containing a) the CD58 extracellular domain or a functional fragment thereof, b) an antigen-binding fragment of an anti-CD3 antibody, and c) the CD80 or CD86 extracellular domain or a functional fragment thereof, and a viral glycoprotein (G protein) on the surface of the particle.

Provided herein are (i) messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) encoding a soluble Nipah virus glycoprotein (soluble NiV-G) fused to a human type I collagen alpha 1 (COL1A1) signal peptide, (ii) an mRNA comprising an ORF encoding the full-length Nipah virus glycoprotein (full-length NiV-G), (iii) an mRNA comprising an ORF encoding the full-length Nipah virus fusion protein (full-length NiV-F), or (iv) an mRNA comprising an ORF encoding full-length NiV-G and an ORF encoding full-length NiV-F, as well as methods for inducing an immune response against Nipah virus by administering an effective amount of the Nipah virus vaccine composition to a subject in need thereof.

The present invention relates to synthetic designs or chimeric proteins for pseudotyping baculovirus (Autographa californica nuclear polyhedrosis virus) with the rabies virus glycoprotein G (gG) on its surface (Bac::gG-FL), which can be used in rabies vaccine formulations. The chimeric protein is designed from a gene cassette containing genetic fragments from the ectodomain of the Pasteur variant rabies virus glycoprotein G, a 7-amino-acid connector sequence (GGGGSGG), as well as transmembrane (TM) and cytoplasmic (CT) regions of the baculoviral protein gp64, the arrangement of which in the designed gene cassette is shown in Figure 1.

Orthotospovirus virions travel through the thrips foregut and enter midgut epithelial cells through the interaction between virus glycoproteins and cellular receptors with several protein motifs thought to be involved in the interaction. Single, double and triple mutant polypeptides in the soybean vein necrosis virus (SVNV) / Neohydatothrips variabilis system are provided herein and several are shown to block viral transmission from the thrips to the soybean plants. Methods for inhibiting viral transmission using these polypeptides or constructs comprising polynucleotides encoding peptides are also provided herein.

The invention discloses a rabies virus glycoprotein chimeric recombinant vesicular stomatitis virus and application thereof, and belongs to the technical field of biological medicine. According to the invention, glycoproteins of two rabies viruses are assembled into the vesicular stomatitis virus vector, and the vesicular stomatitis virus recombinant rabies virus prepared from the vesicular stomatitis virus vector has high virus titer and is convenient for in-vitro culture; a vector vaccine prepared from the recombinant virus can induce animals to generate strong rabies virus neutralizing antibody response through oral immunization, and provides 100% challenge protection for the immunized animals, so that the vaccine can be used as a convenient and effective mucosal immune candidate vaccine; the vaccine has important significance on immunization of rabies virus susceptible wild animals and stray dogs and cats. The oral vaccine provided by the invention overcomes the defects of intramuscular injection vaccines, and provides a basis for the development of novel rabies virus vaccines.

In aspects, the present disclosure provides a recombinant fusion protein comprising, consisting essentially of, or consisting of (a) a rhabdoviral G glycoprotein or a functional fragment or derivative thereof and (b) a targeting molecule, wherein the targeting molecule targets the recombinant fusion protein to a hematopoietic stem cell (HSC). Additional aspects are as described herein.

Disclosed herein are antibodies or antigen binding fragments thereof that specifically bind human CD8. Also disclosed are fusion proteins comprising a Henipavirus glycoprotein G and CD8 antibodies for targeting and transducing cells expressing CD8. Viral vectors and other compositions containing the fusion proteins, as well as methods of using the fusion proteins, are also disclosed.

Provided herein, among other things, are novel and improved glycoproteins, including modified glycoproteins; engineered viral particles comprising such novel and modified glycoproteins; and methods for targeted delivery, for example, to immune cells such as T cells. In some aspects, the engineered viral particles allow targeted delivery of the cargo for various applications, including treating various conditions such as autoimmune diseases and cancer. In some aspects, the engineered viral particles comprise a viral fusogen that is a glycoprotein of Chandipura, Perinet, Piry, Jurona viruses, or variants thereof. In other aspects, the engineered viral particles comprise a modified vesiculovirus glycoprotein mutant, for example, with mutations at amino acids corresponding to positions I347 or R354 of Vesicular Stomatitis Virus G (VSV-G) that reduce binding to Low Density Lipoprotein Receptor (LDL-R).

In aspects, the present disclosure provides a recombinant fusion protein comprising, consisting essentially of, or consisting of (a) a rhabdoviral G glycoprotein or a functional fragment or derivative thereof and (b) a targeting molecule, wherein the targeting molecule targets the recombinant fusion protein to a hematopoietic stem cell (HSC). Additional aspects are as described herein.

The invention discloses a Lassa fever suckling mouse infection model as well as an establishment method and application thereof, belongs to the technical field of biology, and is suitable for a biosafety secondary laboratory. Aiming at the high pathogenicity and biosafety four-level laboratory operation limitation of the lassa virus, a recombinant virus for expressing lassa virus glycoprotein is constructed based on a vesicular stomatitis virus reverse genetics platform, and a lethal infection model is established in a 3-day-old BALB / c suckling mouse; and the dynamic invasion process after the recombinant virus infects the organism can be observed through fluorescence visualization. According to the model, the bio-safety risk of operating the wild type lasa virus in a high-grade bio-safety laboratory is avoided, so that the bio-safety pressure of the laboratory is remarkably reduced; a standardized intraperitoneal injection inoculation mode guarantees experiment repeatability and operation safety; the expensive cost of using high-grade biological safety facilities is avoided, and the method is suitable for research on lasa virus nerve invasion mechanism analysis, antiviral drug blood brain barrier penetration efficiency evaluation and the like.

This application discloses a human monoclonal antibody against Hennipa virus and its preparation and application as a bispecific antibody. By screening memory B cells in fully human antibody-transgenic mice that specifically bind to Nipah virus glycoproteins (G and F proteins), human monoclonal antibodies 14B8 (targeting the F protein) and 4B8 (targeting the G protein) were obtained. Simultaneously, a bispecific antibody 14B8-IgG-4B8-scFv was constructed based on the above antibodies, which is formed by fusing the full antibody (IgG) of 14B8 with a single-chain antibody fragment of 4B8. Experiments demonstrated that the above antibodies exhibit extremely high binding affinity and neutralizing activity against NiV and HeV, and provide excellent in vivo protective efficacy in the LVG Golden Hamster model.

Provided herein are particles comprising a fusion molecule comprising an adhesion molecule linked to a costimulatory molecule or an activation molecule, as well as vectors, such as lentiviral vectors, comprising the same, cells comprising the same, and methods of using the same. The particle may be a lentiviral particle that displays on the surface of the particle a fusion molecule comprising: a) a CD58 extracellular domain, or a functional fragment thereof, b) an antigen-binding fragment of an anti-CD3 antibody, and c) a CD80 or CD86 extracellular domain, or a functional fragment thereof, and a viral glycoprotein (G protein).

Fusion proteins comprising a T cell targeting element and a co-stimulatory molecule and combinations thereof are provided. VSVG virus glycoprotein variants are provided. Also provided is a recombinant virus particle comprising the fusion protein and a VSVG variant. Further provided are uses of the recombinant viral particles for in vivo immune cell therapy.